Público alvo: técnico.
A lista de suplementos para o tratamento de osteoartrose vai se avolumando, além do conjunto tradicional glucosamina/condroitina, colágeno tipo II, Boswellia serrata e outros. Outros já saíram do mercado, como o Piascledine, caro e pouco eficaz na prática clínica. No post de hoje a L-carnitina é notícia, confira a seguir.
- In female patients with knee osteoarthritis (OA), researchers observed reduced inflammatory markers and pain with short-term supplementation of L-carnitine.
- 72 women with mild to moderate knee osteoarthritis started the study and were divided into 2 groups to receive 750 mg/d L-carnitine (n=36) or placebo (n=36) for 8 w.
- Measures of serum levels of Interleukine-1β (IL-1β), high-sensitivity C-reactive protein (hs-CRP), and matrix metalloproteinases (MMPs) -1 and -13.
- Visual analog scale (VAS) for pain was assessed.
- 69 patients (33 in the L-carnitine group and 36 in the placebo group) completed the study.
- L-carnitine supplementation decreased serum IL-1β and MMP-1 levels (P=.001 and .021, respectively).
- In patients taking placebo serum hs-CRP and MMP-13, levels did not change (P>.05); serum IL-1β levels increased significantly (P=.011); other studied biomarkers did not change.
- In the L-carnitine and placebo groups mean VAS score decreased by 52.67% and 21.82%, respectively (P<.001).
- After adjusting for baseline values and covariates, differences were only observed between L-carnitine and placebo groups in serum IL-1β (P<.001), MMP-1 (P=.006), and mean VAS score (P=.002).
- Study was limited to 8 w.
- Inflammatory mediators and metalloproteinase enzymes were only measured in serum, not in the synovial fluids.
Why this matters
- More studies should be done to explore the benefits of L-carnitine, with higher doses of L-carnitine, long-term supplementation, and measures of other inflammatory and anti-inflammatory mediators, including TNF-α, IL-6, IL-10, and MMP-3.